The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksThrogmorton Trust Regulatory News (THRG)

Share Price Information for Throgmorton Trust (THRG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 590.00
Bid: 590.00
Ask: 593.00
Change: -2.00 (-0.34%)
Spread: 3.00 (0.508%)
Open: 591.00
High: 591.00
Low: 590.00
Prev. Close: 592.00
THRG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Portfolio Update

29 Jan 2019 17:16

BlackRock Throgmorton Trust Plc - Portfolio Update

BlackRock Throgmorton Trust Plc - Portfolio Update

PR Newswire

London, January 29

BLACKROCK THROGMORTON TRUST PLC (LEI: 5493003B7ETS1JEDPF59) 

All information is at 31 December 2018 and unaudited.Performance at month end is calculated on a cum income basis

One Month %Three months %One year %Three years %Five years %
Net asset value-5.0-17.8-11.530.655.7
Share price-4.4-20.3-6.626.752.1
Benchmark*-5.2-14.6-16.710.620.1

Sources: BlackRock and Datastream

*With effect from 22 March 2018 the Numis Smaller Companies plus AIM (excluding Investment Companies) Index replaced the Numis Smaller Companies excluding AIM (excluding Investment Companies) Index as the Company’s benchmark. The five year period indices have been blended to reflect this.

At month end
Net asset value capital only:483.82p
Net asset value incl. income:493.19p
Share price437.00p
Discount to cum income NAV11.4%
Net yield1:2.2%
Total Gross assets2:£360.7m
Net market exposure as a % of net asset value3:94.3%
Ordinary shares in issue4:73,130,326
2018 ongoing charges (excluding performance fees)5,6:0.6%
2018 ongoing charges ratio (including performance fees)5,6,7:1.3%

1. Calculated using the 2018 interim dividend declared on 26 July 2018 and paid on 29 August 2018, together with the 2017 final dividend declared on 12 February 2018 and paid on 29 March 2018.

2. Includes current year revenue and excludes gross exposure through contracts for difference.

3. Long positions less short positions as a percentage of net asset value.

4. Excluding 7,400,000 shares held in treasury.

5. Calculated as a percentage of average net assets and using expenses, excluding performance fees and interest costs for the year ended 30 November 2018.

6. With effect from 1 August 2017 the base management fee was reduced from 0.70% to 0.35% of gross assets per annum.

7. Effective 1st December 2017 the annual performance fee is calculated using performance data on an annualised rolling two year basis (previously, one year) and the maximum annual performance fee payable is effectively reduced to 0.90% of two year rolling average month end gross assets (from 1% of average annual gross assets over one year). Additionally, the Company now accrues this fee at a rate of 15% of outperformance (previously 10%). The maximum annual total fees (comprising the base management fee of 0.35% and a potential performance fee of 0.90%) are therefore 1.25% of average month end gross assets on a two year rolling basis (from 1.70% of average annual gross assets).

Sector Weightings% of Total Assets
Financials22.9
Industrials22.7
Consumer Services22.6
Technology10.2
Health Care7.1
Consumer Goods4.8
Basic Materials 3.1
Oil & Gas0.9
Telecommunications 0.6
Net current assets 5.1
-----
Total100.0
=====

Market Exposure (Quarterly)
28.02.18 %31.05.18 %31.08.18 %30.11.18 %
Long119.6115.9119.4103.7
Short8.410.09.610.5
Gross exposure128.0125.9129.0114.2
Net exposure111.2105.9109.893.2

Ten Largest Investments
Company% of Total Gross Assets
SSP3.2
Ascential3.0
Aveva2.8
Craneware2.7
Dechra Pharmaceuticals2.7
YouGov2.5
Integrafin2.5
Bodycote2.4
4imprint Group2.4
Robert Walters2.3

Commenting on the markets, Dan Whitestone, representing the Investment Manager noted:

During December the Company’s NAV per share fell by 5.0%1 to 493.19p on a cum income basis, outperforming our benchmark index, the Numis Smaller Companies plus AIM (excluding Investment Companies) Index, which fell by 5.2%1; the large cap FTSE 100 Index fell by 3.5%1 (all performance figures are in sterling terms with income reinvested).

Equity markets around the world continued to fall during December as disappointing economic data sparked further fears of a slowdown in global growth, while ongoing trade tensions and European political uncertainty added to the concerns. Against the wider market falls, the Company has started its new financial year on a positive note by outperforming its benchmark. In aggregate the long book fell during the month while the short book made a positive contribution of 90bps (basis points).

Within the long book the Company benefitted from a number of core holdings which recovered some of the lost ground in the prior two months. As noted in our October and November updates, the market falls were most heavily concentrated in highly rated growth shares, with a number of holdings falling heavily despite no specific negative newsflow. It was therefore pleasing to see a number of these high quality businesses outperform the falling market, for example SSP, Robert Walters and Integrafin. The Company also benefitted from a strong contribution from UK investment platform AJ Bell, following its successful IPO (Initial Public Offering) during the month. This is a sector that we know well and we had engaged with the company many times ahead of the IPO.

Within the short book we saw a strong contribution from a number of companies that fell in response to negative stock specific newsflow. Most notably a short position in a well known UK electrical retailer fell by nearly 25% off the back of a trading update that resulted in a material downgrade to earnings and cashflow expectations. We also benefitted from some other stock specific shorts in December, reflecting negative market updates.

The largest detractor was from our long position in Craneware, a UK software company focused on the US healthcare market. The shares fell during the month for no specific reason other than being an ‘optically expensive’ growth share. The company did however issue a positive trading update towards the end of December which helped the shares recover some of the losses.

Our financial year has started with a continuation of the elevated levels of volatility seen last year and declining markets globally. We are of the view that this increased volatility looks unlikely to abate in the near term as there are growing challenges to the global growth outlook. With this increased volatility in mind we have continued to run with a lower gross and net exposure than we would have in normal market conditions. Despite this, we continue to believe that there is enough growth in the world for differentiated and disruptive companies to prosper, and we therefore maintain confidence in our long book and for a recovery in many of our investments. As a reminder within the long book we continue to focus on well capitalised companies, with strong and enduring growth prospects that we believe will continue to prosper regardless of the wider macro environment. New shorting opportunities continue to present themselves, so this combined with the market’s reappraisal of financial leverage and the ongoing wave of disruption undermining incumbents’ profit pools should serve us well.

1Source: BlackRock as at 31 December 2018

29 January 2019

ENDS

Latest information is available by typing www.blackrock.co.uk/thrg on the internet, "BLRKINDEX" on Reuters, "BLRK" on Bloomberg or "8800" on Topic 3 (ICV terminal). Neither the contents of the Manager’s website nor the contents of any website accessible from hyperlinks on the Manager’s website (or any other website) is incorporated into, or forms part of, this announcement.

Date   Source Headline
1st Feb 20246:26 pmPRNTransaction in Own Shares
1st Feb 202411:41 amPRNNet Asset Value(s)
1st Feb 20247:00 amPRNTotal Voting Rights
31st Jan 20246:05 pmPRNTransaction in Own Shares
31st Jan 202411:30 amPRNNet Asset Value(s)
31st Jan 20247:00 amPRNTotal Voting Rights
30th Jan 20246:37 pmPRNTransaction in Own Shares
30th Jan 202411:38 amPRNNet Asset Value(s)
30th Jan 20247:00 amPRNTotal Voting Rights
29th Jan 20245:55 pmPRNTransaction in Own Shares
29th Jan 202411:22 amPRNNet Asset Value(s)
29th Jan 20247:00 amPRNTotal Voting Rights
26th Jan 20246:53 pmPRNTransaction in Own Shares
26th Jan 202411:40 amPRNNet Asset Value(s)
26th Jan 20247:00 amPRNTotal Voting Rights
25th Jan 20245:24 pmPRNTransaction in Own Shares
25th Jan 202411:54 amPRNNet Asset Value(s)
25th Jan 202411:14 amPRNPortfolio Update
25th Jan 20247:00 amPRNTotal Voting Rights
24th Jan 20245:41 pmPRNTransaction in Own Shares
24th Jan 202411:22 amPRNNet Asset Value(s)
23rd Jan 20245:40 pmPRNTransaction in Own Shares
23rd Jan 202411:15 amPRNNet Asset Value(s)
22nd Jan 202411:23 amPRNNet Asset Value(s)
19th Jan 202411:10 amPRNNet Asset Value(s)
18th Jan 202411:35 amPRNNet Asset Value(s)
18th Jan 20247:00 amPRNTotal Voting Rights
17th Jan 202411:30 amPRNNet Asset Value(s)
17th Jan 20247:00 amPRNTotal Voting Rights
16th Jan 20245:47 pmPRNTransaction in Own Shares
16th Jan 202411:45 amPRNNet Asset Value(s)
15th Jan 20245:52 pmPRNTransaction in Own Shares
15th Jan 202411:52 amPRNNet Asset Value(s)
12th Jan 202411:18 amPRNNet Asset Value(s)
12th Jan 20247:00 amPRNTotal Voting Rights
11th Jan 202411:45 amPRNNet Asset Value(s)
10th Jan 20246:22 pmPRNTransaction in Own Shares
10th Jan 202411:43 amPRNNet Asset Value(s)
9th Jan 202411:37 amPRNNet Asset Value(s)
8th Jan 202411:51 amPRNNet Asset Value(s)
8th Jan 20247:00 amPRNTotal Voting Rights
5th Jan 202411:58 amPRNNet Asset Value(s)
4th Jan 20246:33 pmPRNTransaction in Own Shares
4th Jan 202411:34 amPRNNet Asset Value(s)
3rd Jan 20242:07 pmPRNNet Asset Value(s)
3rd Jan 20247:00 amPRNTotal Voting Rights
2nd Jan 20242:57 pmPRNTotal Voting Rights
2nd Jan 202412:18 pmPRNNet Asset Value(s)
29th Dec 20234:02 pmPRNTransaction in Own Shares
29th Dec 202312:27 pmPRNMandatory Closed Period Compliance with MAR

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.